BCR–ABL1 became a therapeutic target for leukaemic cells and paved the way for the development of tyrosine kinase inhibitors (TKI) that dramatically improved the survival of CML patients [8,9]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.